Clinical Trial Update: Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating three doses of TAS-108 for recurrent or inoperable breast cancer has completed. The trial was sponsored by SRI International.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TAS-108

Snippet

Sponsor: SRI International | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED